AbTherx
- Biotech or pharma, therapeutic R&D
AbTherx is revolutionizing therapeutic antibody discovery with a next-gen platform for complex targets and multispecifics. Through an exclusive license from Gilead Sciences, AbTherx has released Atlas™ Mice, a suite of novel transgenic technologies.
Binary Fixed Light Chain Mouse streamlines the engineering, development, and manufacturing of bispecific antibodies, optimizing the process for greater efficiency.
Long CDR3 Mouse leverages a rare, naturally occurring phenomenon to simplify targeting complex transmembrane proteins, such as GPCRs and ion channels, enhancing the precision of antibody-based therapeutics.
Full Human Diversity Mouse is an updated industry standard that generates human antibodies with the affinities and diversity required for efficient and successful therapeutic development.
AbTherx was founded by senior leaders of Medarex, Bristol Myers Squibb, and Zai Lab's antibody discovery and technology teams, and the previous leadership team of AlivaMab Biologics.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}